1. A protease inhibitor and an integrase strand transfer inhibitor (INSTI) both interrupt HIV replication, but they differ in the stage of the replication cycle at which functional blockade produces non-infectious virus. Which statement most precisely distinguishes the protease inhibitor's point of action?
A) Protease inhibition blocks reverse transcription of viral RNA into DNA before nuclear entry
B) Protease inhibition acts at viral maturation, so that particles still bud from the cell but are rendered morphologically immature and non-infectious because Gag and Gag-Pol polyproteins are not cleaved
C) Protease inhibition prevents insertion of viral DNA into the host chromosome during the strand transfer step
D) Protease inhibition blocks attachment of the virion to the host CD4 (cluster of differentiation 4) receptor
E) Protease inhibition prevents fusion of the viral envelope with the host membrane
ANSWER: B
Rationale:
Protease inhibitors act late in the cycle: HIV-1 protease cleaves the Gag and Gag-Pol polyproteins during and after budding, and without that cleavage the released particle is morphologically immature and non-infectious. The virion still buds; it is simply not infectious.
Option B: Option B states this maturation-stage mechanism precisely.
Option A: Option A describes reverse transcriptase inhibition, an earlier intracellular step.
Option C: Option C describes the integrase strand transfer step targeted by INSTIs, not protease.
Option D: Option D describes an attachment inhibitor acting on CD4 binding.
Option E: Option E describes a fusion inhibitor acting at membrane fusion. Only Option B correctly localizes the protease inhibitor to post-budding maturation.
2. Ritonavir and cobicistat are both used as pharmacokinetic boosters that potently inhibit cytochrome P450 3A4 (CYP3A4). Which statement correctly identifies a pharmacological difference between them that affects their drug interaction profiles?
A) Cobicistat retains intrinsic antiviral activity, whereas ritonavir does not
B) Cobicistat inhibits CYP2D6 and CYP2C9 in addition to CYP3A4, giving it a broader interaction profile than ritonavir
C) Ritonavir raises serum creatinine through multidrug and toxin extrusion protein 1 (MATE1) inhibition, whereas cobicistat has no effect on creatinine
D) Ritonavir inhibits additional isoforms beyond CYP3A4 (including CYP2D6 and CYP2C9), giving it a broader interaction profile, whereas cobicistat is a comparatively more selective CYP3A4 inhibitor
E) Ritonavir cannot be combined with any protease inhibitor, whereas cobicistat can
ANSWER: D
Rationale:
Both agents are potent CYP3A4 inhibitors used purely as boosters, but ritonavir also inhibits CYP2D6, CYP2C9, and several other isoforms, producing a broader interaction footprint; cobicistat is comparatively more selective for CYP3A4, which somewhat narrows its interaction profile.
Option D: Option D states this correctly. Option A is reversed: neither booster has meaningful intrinsic antiviral activity at booster doses, and cobicistat was developed specifically as a booster without antiviral effect.
Option B: Option B attributes the broader isoform inhibition to cobicistat, the reverse of the truth.
Option C: Option C inverts the creatinine relationship: it is cobicistat (via MATE1 inhibition), not ritonavir, that characteristically raises serum creatinine as an artifact. Option E is false because both boosters are used with protease inhibitors.
3. A patient on a cobicistat-containing single-tablet regimen has a stable serum creatinine that rose 0.15 mg/dL shortly after starting therapy, with an unchanged measured iohexol clearance and no proteinuria. Which interpretation is most accurate?
A) The estimated glomerular filtration rate has fallen because cobicistat inhibits tubular secretion of creatinine via multidrug and toxin extrusion protein 1 (MATE1), raising serum creatinine while true filtration, confirmed here by the unchanged iohexol clearance, is preserved
B) The patient has developed cobicistat-induced acute tubular necrosis and the regimen must be discontinued
C) The creatinine rise reflects a true decline in glomerular filtration that contradicts the iohexol result, which should be disregarded
D) Cobicistat has caused immune-complex glomerulonephritis, explaining the creatinine change despite absent proteinuria
E) The finding indicates rhabdomyolysis from a drug interaction and creatine kinase need not be checked
ANSWER: A
Rationale:
Cobicistat inhibits MATE1, the transporter that mediates tubular secretion of creatinine. Blocking secretion raises serum creatinine and lowers the estimated glomerular filtration rate (eGFR), but a direct measure of filtration such as iohexol clearance remains unchanged because true glomerular filtration is not impaired. Option A integrates the lab pattern correctly. Option B is wrong because acute tubular necrosis would not present as an isolated small creatinine rise with preserved measured clearance and no other findings. Option C improperly discards the gold-standard filtration measurement to force a true-GFR interpretation. Option D invokes glomerulonephritis, which is inconsistent with the absence of proteinuria and the benign artifact picture.
Option E: Option E misattributes the finding to rhabdomyolysis and wrongly dismisses creatine kinase testing.
4. Darunavir is described as having an exceptionally high genetic barrier to resistance compared with older protease inhibitors. Which mechanistic explanation best accounts for this property?
A) Darunavir irreversibly alkylates the protease active site, so resistance cannot develop
B) Darunavir targets a host enzyme rather than viral protease, so the virus cannot mutate to escape it
C) Darunavir forms an extensive hydrogen bond network with the conserved protease backbone, so that meaningful resistance requires the simultaneous accumulation of at least three major active-site mutations, each carrying a fitness cost
D) Darunavir is a prodrug that the virus cannot recognize until activated, preventing resistance selection
E) Darunavir achieves such high plasma concentrations that resistance mutations are pharmacologically irrelevant at any level
ANSWER: C
Rationale:
Darunavir binds the protease active site with very high affinity and forms a hydrogen bond network with the relatively conserved protease backbone rather than with side chains that mutate easily. Disrupting that network requires several simultaneous major active-site mutations, and because protease must retain catalytic function, each mutation carries a fitness cost—together producing a high genetic barrier in which roughly three or more major resistance-associated mutations must co-occur for clinical failure. Option C captures this.
Option A: Option A is incorrect because darunavir is a reversible competitive inhibitor, not an irreversible alkylator. Option B is wrong because darunavir targets viral protease, not a host enzyme.
Option D: Option D is incorrect; darunavir is not an intracellularly activated prodrug, and that would not explain a resistance barrier.
Option E: Option E overstates pharmacokinetics; concentration alone does not render resistance mutations irrelevant, and high-level multi-mutation resistance does reduce susceptibility.
5. Atazanavir produces two distinct and unrelated adverse effects that are sometimes confused. Which option correctly pairs each effect with its mechanism?
A) Both jaundice and kidney stones result from atazanavir crystal deposition in tissues
B) Jaundice results from hemolysis, while kidney stones result from uricosuria
C) Jaundice results from hepatocellular necrosis, while kidney stones result from renal tubular acidosis
D) Jaundice results from biliary obstruction, while kidney stones result from hypercalciuria
E) Jaundice results from inhibition of uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) causing benign unconjugated hyperbilirubinemia, while nephrolithiasis results from precipitation of atazanavir-containing crystals in the urinary tract
ANSWER: E
Rationale:
Atazanavir inhibits UGT1A1, impairing bilirubin conjugation and producing benign, reversible unconjugated hyperbilirubinemia with scleral icterus; separately, atazanavir can precipitate as crystals in the urinary tract, causing nephrolithiasis in a small percentage of long-term users. These are two mechanistically independent effects, correctly paired in Option E. Option A wrongly attributes the jaundice to crystal deposition; the jaundice is a conjugation defect, not crystal-related.
Option B: Option B is incorrect because the hyperbilirubinemia is from impaired conjugation, not hemolysis, and the stones are atazanavir crystals, not urate. Option C is wrong because the bilirubin rise is unconjugated and benign, not from hepatocellular necrosis.
Option D: Option D misattributes the jaundice to biliary obstruction and the stones to hypercalciuria, neither of which is the atazanavir mechanism.
6. Integrase performs two sequential catalytic reactions: 3-prime processing and strand transfer. Integrase strand transfer inhibitors (INSTIs) are selective for one of these. Which statement correctly describes the basis of that selectivity?
A) INSTIs block 3-prime processing in the cytoplasm by preventing removal of the terminal dinucleotides from the viral DNA ends
B) INSTIs chelate the two active-site magnesium ions required for the strand transfer reaction, blocking insertion of the processed viral DNA into host chromosomal DNA while leaving the earlier 3-prime processing step largely intact
C) INSTIs inhibit both reactions equally by denaturing the integrase enzyme
D) INSTIs prevent nuclear import of the pre-integration complex, so neither reaction can occur
E) INSTIs act on reverse transcriptase to prevent formation of the viral DNA substrate that integrase requires
ANSWER: B
Rationale:
INSTIs contain a metal-chelating pharmacophore that coordinates the two magnesium ions in the integrase active site. This metal coordination is specifically required for the strand transfer reaction—the nuclear insertion of processed viral DNA into host DNA—so INSTIs block strand transfer while the earlier cytoplasmic 3-prime processing step is largely unaffected.
Option B: Option B states this selective mechanism, which is the basis for the class name. Option A misassigns the target to 3-prime processing.
Option C: Option C is incorrect because INSTIs act by specific active-site metal chelation, not nonspecific enzyme denaturation, and are not equipotent against both reactions.
Option D: Option D describes a capsid inhibitor effect on nuclear import, not an INSTI mechanism.
Option E: Option E describes reverse transcriptase inhibition, a different enzyme and class.
7. A patient failing raltegravir is found to carry an N155H (asparagine-155-histidine) integrase mutation. The team asks why dolutegravir often retains activity against viruses that have defeated raltegravir. Which explanation is correct?
A) Dolutegravir is given at a far higher milligram dose, so it overcomes any integrase mutation purely by concentration
B) Dolutegravir targets reverse transcriptase rather than integrase, so integrase mutations do not affect it
C) Dolutegravir requires cobicistat boosting, and the booster independently suppresses resistant virus
D) Dolutegravir has a flexible binding mode that adapts to the minor active-site conformational changes caused by first-generation signature mutations such as N155H, so single mutations that abolish raltegravir activity reduce dolutegravir susceptibility only minimally
E) Dolutegravir works only against CXCR4-tropic virus, and raltegravir failure selects for that tropism
ANSWER: D
Rationale:
Dolutegravir is a second-generation INSTI whose flexible molecular structure adjusts to the small active-site conformational changes produced by first-generation resistance mutations such as N155H, Y143, and Q148. As a result, single mutations that confer high-level raltegravir resistance reduce dolutegravir susceptibility only minimally, which is the basis of its higher barrier. Option D explains this correctly. Option A is wrong because the durability comes from binding adaptability, not from sheer dose overcoming resistance. Option B misassigns dolutegravir's target to reverse transcriptase; it is an integrase inhibitor.
Option C: Option C is incorrect because dolutegravir does not require cobicistat boosting, and boosting would not explain retained activity against resistant integrase.
Option E: Option E confuses INSTI activity with co-receptor tropism, which is irrelevant to integrase inhibition.
8. Among the integrase strand transfer inhibitors (INSTIs), elvitegravir differs from dolutegravir and bictegravir in a way that meaningfully affects its drug interaction profile. Which statement is correct?
A) Elvitegravir requires cobicistat boosting because its unboosted half-life is insufficient for once-daily dosing, and that boosting imports the full cytochrome P450 3A4 (CYP3A4)-inhibitor interaction burden, including the creatinine artifact and statin interactions
B) Elvitegravir is the only INSTI that needs no boosting and has no clinically relevant drug interactions
C) Elvitegravir is boosted with ritonavir to provide additional antiviral activity beyond integrase inhibition
D) Elvitegravir is unique among INSTIs in being eliminated entirely unchanged by the kidney, requiring renal dose adjustment
E) Elvitegravir must be co-administered with a protease inhibitor to achieve adequate plasma levels
ANSWER: A
Rationale:
Elvitegravir's half-life without enhancement is too short for once-daily dosing, so it is co-formulated with cobicistat. That booster brings the full CYP3A4-inhibitor interaction burden—including the creatinine secretion artifact, statin interactions, and incompatibility with strong inducers such as rifampin—which is the key contrast with the unboosted second-generation agents dolutegravir and bictegravir. Option A is correct.
Option B: Option B describes dolutegravir/bictegravir, not elvitegravir, and is therefore wrong.
Option C: Option C is incorrect because the booster is cobicistat (not ritonavir for added antiviral effect) and boosters contribute no antiviral activity. Option D is wrong because INSTIs as a class are not eliminated unchanged by the kidney and do not require renal dose adjustment.
Option E: Option E is incorrect; elvitegravir is boosted by cobicistat, not by a protease inhibitor.
9. Maraviroc differs from most antiretrovirals in that resistance does not typically arise from mutation of the drug-binding site. Which statement best explains maraviroc's resistance behavior and the consequence for prescribing?
A) Resistance arises from mutations in HIV protease, so protease genotyping must precede maraviroc use
B) Resistance arises from integrase mutations identical to those seen with raltegravir
C) Because maraviroc blocks the host CCR5 (C-C chemokine receptor type 5) co-receptor, escape occurs chiefly through a shift to CXCR4 (C-X-C chemokine receptor type 4)-using virus; any detectable X4 or dual/mixed-tropic population predicts failure, so a validated tropism assay confirming exclusively R5 virus is required before use
D) Resistance is impossible because maraviroc targets a host protein, so tropism testing is unnecessary
E) Resistance arises from reverse transcriptase mutations, so maraviroc requires the same resistance testing as nucleoside analogues
ANSWER: C
Rationale:
Maraviroc binds the host CCR5 co-receptor, so the virus does not need to mutate the drug-binding site to escape; instead, escape occurs through use of the alternative CXCR4 co-receptor (a tropism shift) or by outgrowth of pre-existing X4 or dual/mixed-tropic virus. Because maraviroc has no activity against CXCR4-using virus, any detectable X4 population predicts failure, and a validated tropism assay confirming exclusively R5 virus is mandatory before prescribing. Option C is correct. Option A is wrong because protease genotyping is irrelevant to a CCR5 antagonist.
Option B: Option B incorrectly assigns integrase resistance pathways to maraviroc. Option D wrongly concludes that targeting a host protein eliminates resistance and the need for tropism testing—tropism shift is precisely the escape route.
Option E: Option E misattributes reverse transcriptase resistance testing to maraviroc.
10. A clinician must choose lipid-lowering therapy for a patient on darunavir/ritonavir. Which statement correctly stratifies statin choice by interaction risk in this setting?
A) Simvastatin and lovastatin are preferred; pravastatin and rosuvastatin are contraindicated
B) All statins are equally safe because the booster lowers every statin's concentration uniformly
C) Atorvastatin is absolutely contraindicated, while simvastatin may be used at full dose
D) Rosuvastatin is contraindicated because it is heavily CYP3A4-metabolized, while simvastatin is preferred because it is not
E) Simvastatin and lovastatin are contraindicated because CYP3A4 inhibition by the booster raises their concentrations dramatically; pravastatin and rosuvastatin are preferred because they are minimally CYP3A4-metabolized; atorvastatin may be used cautiously at the lowest effective dose
ANSWER: E
Rationale:
Boosted protease inhibitors strongly inhibit CYP3A4. Statins heavily dependent on CYP3A4—simvastatin and lovastatin—accumulate to dangerous concentrations and are contraindicated; pravastatin and rosuvastatin are minimally CYP3A4-metabolized and are preferred; atorvastatin sits in between and may be used cautiously at the lowest effective dose with monitoring.
Option E: Option E states this stratification correctly.
Option A: Option A inverts the safe and unsafe agents. Option B is wrong because boosting raises CYP3A4-dependent statin levels rather than uniformly lowering all statins. Option C wrongly contraindicates atorvastatin while endorsing full-dose simvastatin, the most dangerous choice.
Option D: Option D reverses the metabolic facts: rosuvastatin is minimally CYP3A4-metabolized and preferred, while simvastatin is the CYP3A4-dependent agent to avoid.
11. A patient on a boosted protease inhibitor regimen needs treatment for active tuberculosis. Which statement correctly distinguishes rifampin from rifabutin in this setting?
A) Both rifampin and rifabutin are contraindicated with all boosted protease inhibitors and cannot be used under any circumstance
B) Rifampin is contraindicated because it is a potent CYP3A4 inducer that collapses protease inhibitor exposure, whereas rifabutin is a much weaker inducer and can generally be used with a reduced rifabutin dose alongside the boosted PI
C) Rifampin is preferred with boosted PIs because the booster offsets its induction, whereas rifabutin must be avoided
D) Rifabutin is contraindicated because the boosted PI lowers rifabutin levels to subtherapeutic, whereas rifampin is safe
E) Neither drug interacts with boosted PIs, so standard doses of either may be used without adjustment
ANSWER: B
Rationale:
Rifampin is a potent inducer of CYP3A4 and reduces protease inhibitor area under the concentration-time curve by roughly 75 to 90%, defeating the boosting strategy, so it is contraindicated with boosted PIs. Rifabutin is a substantially weaker inducer and can generally be used, with the rifabutin dose reduced because the boosted PI raises rifabutin exposure.
Option B: Option B states this contrast correctly. Option A is wrong because rifabutin is usable with dose adjustment.
Option C: Option C is incorrect because the booster does not offset rifampin's induction; rifampin remains contraindicated.
Option D: Option D inverts the interaction direction and the safety conclusion. Option E falsely claims no interaction, ignoring rifampin's potent induction.
12. A patient taking dolutegravir also uses a calcium-containing antacid and an oral iron supplement. Which counseling on administration timing is most accurate for preventing a chelation interaction?
A) The antacid and iron may be taken at the exact same time as dolutegravir with no effect on absorption
B) Dolutegravir should be permanently discontinued whenever any cation-containing product is required
C) Dolutegravir absorption is increased by simultaneous cation intake, so co-administration is encouraged
D) Dolutegravir should be separated from cation-containing antacids and supplements—taken at least 2 hours before or 6 hours after these products—although taking dolutegravir together with calcium or iron is acceptable if all are taken with food
E) Only aluminum-containing antacids interact with dolutegravir; calcium and iron have no effect
ANSWER: D
Rationale:
INSTIs chelate polyvalent cations (calcium, magnesium, iron, aluminum), and co-ingestion reduces absorption. For dolutegravir the standard rule is to separate dosing—taking dolutegravir at least 2 hours before or 6 hours after cation-containing antacids or supplements—while co-administration with calcium or iron is acceptable when taken together with food.
Option D: Option D states this correctly. Option A is wrong because simultaneous intake on an empty stomach reduces absorption. Option B is excessive; separation, not discontinuation, manages the interaction.
Option C: Option C inverts the effect: cations decrease, not increase, INSTI absorption.
Option E: Option E is incorrect because calcium and iron, not only aluminum, chelate and reduce dolutegravir absorption.
13. Two second-generation integrase strand transfer inhibitors, dolutegravir and bictegravir, are handled differently when rifampin is required. Which statement correctly distinguishes them?
A) Dolutegravir can be continued with rifampin by doubling its dose to 50 mg twice daily to offset enzyme induction, whereas bictegravir is contraindicated with rifampin because dose adjustment is not established for the fixed-dose combination and the interaction magnitude is greater
B) Both dolutegravir and bictegravir require no change with rifampin because neither is affected by induction
C) Bictegravir is continued by doubling its dose, whereas dolutegravir is contraindicated with rifampin
D) Dolutegravir must be halved when rifampin is added to prevent accumulation, whereas bictegravir is unaffected
E) Both agents are simply replaced by elvitegravir, which is unaffected by rifampin
ANSWER: A
Rationale:
Rifampin induces the UGT1A1 and CYP3A4 pathways that clear these agents. For dolutegravir, doubling the dose to 50 mg twice daily restores adequate exposure and allows co-administration; for bictegravir, dose adjustment within its fixed-dose combination is not established and the interaction is greater, so it is contraindicated with rifampin. Option A captures this distinction. Option B is wrong because both are affected by induction.
Option C: Option C reverses which agent can be dose-adjusted.
Option D: Option D inverts the direction of adjustment—induction lowers exposure, so dolutegravir is doubled, not halved.
Option E: Option E is incorrect because elvitegravir, being cobicistat-boosted, is also incompatible with rifampin and is not a rifampin-safe substitute.
14. Enfuvirtide and ibalizumab are both injectable agents acting at the entry stage, but their molecular targets differ. Which option correctly pairs each agent with its target and route?
A) Enfuvirtide binds CD4 (cluster of differentiation 4) domain 2 intravenously, while ibalizumab binds gp41 subcutaneously
B) Both bind the CCR5 (C-C chemokine receptor type 5) co-receptor, differing only in dosing interval
C) Enfuvirtide is a subcutaneously injected peptide that binds the gp41 HR1 (heptad repeat 1) region to block six-helix bundle formation and membrane fusion, whereas ibalizumab is an intravenous monoclonal antibody that binds CD4 (cluster of differentiation 4) domain 2 to block the post-attachment conformational change needed for co-receptor engagement
D) Both target HIV protease and differ only in molecular size
E) Enfuvirtide binds integrase while ibalizumab binds reverse transcriptase
ANSWER: C
Rationale:
Enfuvirtide is a synthetic peptide given by subcutaneous injection that binds the gp41 HR1 region, preventing six-helix bundle formation and thus membrane fusion. Ibalizumab is a humanized monoclonal antibody given intravenously that binds domain 2 of the host CD4 receptor, blocking the post-attachment conformational change required for co-receptor engagement without disturbing CD4's immune function. Option C pairs both correctly. Option A swaps the two agents' targets and routes. Option B is wrong because neither agent is a CCR5 antagonist.
Option D: Option D incorrectly assigns both to protease. Option E misassigns enfuvirtide to integrase and ibalizumab to reverse transcriptase.
15. A patient on long-acting injectable cabotegravir plus rilpivirine (CAB+RPV) decides to stop the injections. Why is the prolonged pharmacokinetic tail of these drugs clinically important, and what is the recommended action?
A) The tail is irrelevant because both drugs clear within 24 hours of the last injection
B) The tail means the drugs accumulate to toxic levels, so the patient should be hospitalized for monitoring
C) The tail requires immediate plasmapheresis to remove residual drug
D) The tail indicates the regimen was subtherapeutic, so no further antiretroviral coverage is needed
E) After the last injection, declining subtherapeutic concentrations can persist for many months (cabotegravir) to years (rilpivirine), creating a functional monotherapy window that can select resistance; oral antiretroviral therapy should be started promptly—about the day after the last injection would have been due—to provide full coverage
ANSWER: E
Rationale:
Both injectable drugs are absorbed slowly from the depot and have prolonged terminal concentrations after the last dose—cabotegravir detectable for many months and rilpivirine for up to years in some individuals. As levels decline below therapeutic thresholds, the patient effectively receives waning monotherapy, which can select resistance; therefore oral ART should be started promptly, roughly the day after the next injection would have been due, to maintain full coverage.
Option E: Option E states the mechanism and the action correctly. Option A is wrong because the drugs do not clear within a day. Option B mischaracterizes the tail as toxic accumulation requiring hospitalization.
Option C: Option C is incorrect because plasmapheresis is not used or needed. Option D wrongly concludes no coverage is required, ignoring the resistance risk of the monotherapy window.
16. Several antiretrovirals are now given by injection at extended intervals. Which option correctly distinguishes lenacapavir from the other long-acting injectables by mechanism and dosing interval?
A) Lenacapavir is an integrase inhibitor given intramuscularly every month, identical to cabotegravir
B) Lenacapavir is a capsid inhibitor—disrupting capsid assembly and nuclear import of the pre-integration complex—given by subcutaneous injection every six months, distinct from intramuscular cabotegravir plus rilpivirine (monthly or every two months) and from intravenous ibalizumab (every two weeks)
C) Lenacapavir is a monoclonal antibody against CD4 (cluster of differentiation 4) given intravenously every two weeks, identical to ibalizumab
D) Lenacapavir is a non-nucleoside reverse transcriptase inhibitor given subcutaneously every two months, identical to rilpivirine
E) Lenacapavir is a protease inhibitor given orally once daily and is not a long-acting injectable
ANSWER: B
Rationale:
Lenacapavir is a first-in-class capsid inhibitor that disrupts the HIV-1 capsid, including capsid assembly and nuclear import of the pre-integration complex, and it is administered subcutaneously every six months—the longest interval among approved antiretroviral injectables. This sets it apart from intramuscular cabotegravir plus rilpivirine (given monthly or every two months) and from intravenous ibalizumab (every two weeks).
Option B: Option B states the mechanism and interval correctly and contrasts the other agents accurately. Option A wrongly calls it a monthly intramuscular integrase inhibitor like cabotegravir.
Option C: Option C misidentifies it as a CD4 monoclonal like ibalizumab. Option D misclassifies it as an NNRTI like rilpivirine.
Option E: Option E incorrectly labels it an oral daily protease inhibitor, contradicting its capsid-inhibitor mechanism and six-month subcutaneous dosing.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.